Health
Cyberattack on UnitedHealth firm forces doctors to dig into personal savings to stay afloat
Omar Marques | Lightrocket | Getty Images On a Sunday in early March, Dr. Angeli Maun Akey noticed something peculiar while making payroll for her private practice in Gainesville, Florida: She was missing $19,000. Akey owns and operates a primary care practice that serves around 3,500 patients in the area, many of whom suffer from […]
Read More
Jim Cramer says GE Healthcare’s unwarranted post-earnings plunge is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) April showers : The Dow Jones […]
Read More
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster drugs Ozempic, Saxenda and Victoza. The […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. Mike Blake | Reuters Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss […]
Read More
Walmart to shutter health centers, virtual care service in latest failed push into health care
Walmart on Tuesday said it will close all of its health-care clinics across the country, a stunning reversal of its plans to bring its low-priced reputation to the dentist and doctor’s office along with the grocery aisle. The big-box retailer said it would also shutter its telehealth provider, which it acquired for an undisclosed amount […]
Read More
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
Jonathan Raa | Nurphoto | Getty Images A federal judge in New Jersey on Monday rejected Johnson & Johnson‘s and Bristol Myers Squibb‘s legal challenges to the Biden administration’s Medicare drug-price negotiations, ruling that the program is constitutional. The decision is another win for the White House in a bitter legal fight with several drugmakers […]
Read More
Why Eli Lilly’s earnings are no sure thing for traders despite obesity drug momentum
Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company’s earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly’s diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The Food and Drug Administration recently reported […]
Read More
Biden administration delays plans to ban menthol cigarettes
U.S. President Joe Biden speaks after signing into law a bill providing billions of dollars of new aid to Ukraine for its war with Russia, at the White House in Washington, U.S., April 24, 2024. Elizabeth Frantz | Reuters The Biden Administration has delayed plans to ban menthol cigarettes, a proposal announced by the Food […]
Read More
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
Pavlo Gonchar | Lightrocket | Getty Images The Food and Drug Administration on Friday approved Pfizer‘s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B […]
Read More